EUVIMEDEUVIMED entdecken
Crossref

Anti-CTLA-4 Antibody Might Be Effective Against Non-small Cell Lung Cancer With Large Size Tumor

Hiroshi Saijo, Yoshihiko Hirohashi, Osamu Honjo, Toyohiro Saikai, Naoki Shijubo, Hirotsugu Takabatake, Akihisa Fujita, Yasuhito Honda, Hiroyuki Koba, Hirofumi Chiba, Toshihiko Torigoe

Anticancer Research · 2023

DOI: 10.21873/anticanres.16606 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2023. Verfasst von Hiroshi Saijo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Sapporo Minami-Sanjo Hospital, Sapporo, Japan; h_saijo@h-keiaikai.or.jp. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Immunotherapy using immune checkpoint inhibitors (ICIs) has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). Although several ICI options are available, the treatment regimen for NSCLC with large size tumors (large NSCLC) is controversial and the efficacy of anti-CTLA-4 antibody is unclear. This study thus investigated potential biomarkers for CTLA-4 blockade. PATIENTS AND METHODS: The correlation between tumor diameter and treatment duration was examined in patients with advanced NSCLC treated with anti-PD-1 antibody monotherapy in our institution. In addition, the ratio of tumor-infiltrating CD8+ T cells and regulatory T (Treg) cells in small and large size NSCLC was also evaluated using immunohistochemical staining. Finally, the efficacy of treatment with anti-CTLA-4 antibody against large NSCLC was investigated. RESULTS: A negative correlation was found between tumor diameter and treatment duration in patients treated with anti-PD-1 antibody monotherapy. Immuno-histochemical staining revealed that Treg cell infiltration was significantly higher in large NSCLC tumors than in small tumors. Among the patients with large NSCLC, the ICI regimen including anti-CTLA-4 antibody showed significant efficacies. CONCLUSION: Anti-PD-1 antibody monotherapy might be less effective against large NSCLC due to the infiltration of Treg cells. Therefore, it might be appropriate for large NSCLC to select a treatment including an anti-CTLA-4 antibody, which can target Treg cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansCD8-Positive T-LymphocytesDuration of TherapyImmunotherapy

Stichwörter der Autor:innen

NSCLCTreg cellsanti-CTLA-4 antibodybiomarkertumor size

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Sapporo Minami-Sanjo Hospital, Sapporo, Japan; h_saijo@h-keiaikai.or.jp.
  • Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan.
  • Department of Respiratory Medicine, Sapporo Minami-Sanjo Hospital, Sapporo, Japan.
  • Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan.

Zitieren

APA

Saijo, H., Hirohashi, Y., Honjo, O., Saikai, T., Shijubo, N., Takabatake, H., Fujita, A., Honda, Y., Koba, H., Chiba, H., & Torigoe, T. (2023). Anti-CTLA-4 Antibody Might Be Effective Against Non-small Cell Lung Cancer With Large Size Tumor. Anticancer Research. https://doi.org/10.21873/anticanres.16606

Vancouver

Saijo H, Hirohashi Y, Honjo O, Saikai T, Shijubo N, Takabatake H, et al. Anti-CTLA-4 Antibody Might Be Effective Against Non-small Cell Lung Cancer With Large Size Tumor. Anticancer Research. 2023. doi:10.21873/anticanres.16606

BibTeX
@article{Saijo2023,
  author = {Saijo, Hiroshi and Hirohashi, Yoshihiko and Honjo, Osamu and Saikai, Toyohiro and Shijubo, Naoki and Takabatake, Hirotsugu and Fujita, Akihisa and Honda, Yasuhito and Koba, Hiroyuki and Chiba, Hirofumi and Torigoe, Toshihiko},
  title = {Anti-CTLA-4 Antibody Might Be Effective Against Non-small Cell Lung Cancer With Large Size Tumor},
  journal = {Anticancer Research},
  year = {2023},
  doi = {10.21873/anticanres.16606}
}
Kostenlos starten →